MS Stats v3-03
The total estimated yearly cost of MS in the United States is $28B.
Globally, an estimated 2.5 million people have MS.

Deeper insights into the drivers of multiple sclerosis

Multiple sclerosis is a complex disease. Recent therapeutic advances focus on disease-modifying therapies - reducing the rate of progression or the frequency of relapse. Most of these therapies help patients with relapsing-recurring MS (RRMS). Unfortunately, patients with secondary or primary progressive MS (SPMS, PPMS) have not benefitted from the same progress. 

Several genetic variants are known to influence the risk of multiple sclerosis. Some of these variants are now being investigated as therapeutic targets. However, connecting disease severity or progression to genetic factors in large-scale genetic studies is difficult without detailed clinical history.

Genuity Science's MS clinicogenomic dataset covers a comprehensive discovery cohort enriched for SPMS and PPMS, also including RRMS participants. Detailed clinical and laboratory data help define disease subtype, severity, and rate of progression.  Genomic data includes whole genome sequencing at a typical 30x depth along with other -omic and deep phenotypic data from several thousand participants. 

Genuity Science partners with drug discovery teams in many disease areas to provide answers to their toughest research questions.  Learn more about our approach below and see how deeper, richer datasets can accelerate your research program.

Additional details on Genuity's multiple sclerosis dataset are available in the datasheet

Show me

Hear from the scientists working on our multiple sclerosis study 

"When I read about the study being undertaken by Genuity Science it was a ‘no brainer for me’; I just had to take part."

Read his story

Photo of Declan Groeger

Declan Groeger
MS Research Study Participant

Target Discovery Diagram

The Genuity Science Approach

We start by combining population-scale high quality whole genome sequence data with detailed clinical phenotype data to help distinguish signal from noise for a given disease. Distilling candidate targets from initial hits requires several layers of analysis.  These analysis phases work like a funnel to narrow down and genomically validate hits.  Our experienced team of scientists works with you every step of the way with a goal of delivering candidate targets for your drug development program.  

Anthony Ryan

Deep Phenotyping

In this webinar, Genuity Science Principal Scientist Anthony Ryan, PhD discusses the importance and value of deep phenotyping when looking for genomic associations to disease.

Learn More

Photo of the Genuity Science sequencing lab.

Virtual Lab Tour

Take a look inside Genuity Science’s CAP accredited lab located in Dublin, Ireland.

Watch Now

Photo of Howard Jacob

In Sequence

In this episode of Genuity Science's In Sequence podcast, AbbVie VP and head of genomic research Howard Jacob, PhD talks about the importance of genomic research in his disease programs.

Listen here 

Interested in learning more? Let's talk.